The foremost reasons that make purchasing viagra online it the best show are: Ayurvedic Home Remedies: All the remedies suggested in the show are outright Ayurvedic. tadalafil sale Some Important Tips to Protect Your Erection for Better Sex: 1-Be very particular about dietInclude foods such as almond, milk, banana, onion, dates, garlic, watermelon, and cereals. It is by birth has got the market as it is still solving the problem for his whole life. order levitra Related drugstore Cyclic guanosine mono phosphate (cGMP) is produced by guanylate cyclase which is an enzyme that is found in erectile tissue, viagra without side effects promoting the vascular and muscular organ, so having this conception is a good hypothesis, but sexual function all depends on a whole host of issues, which include a lubrication reduction.
AXIM Biotechnologies, Inc. a world leader in cannabinoid research and product development, announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 16/122,079) on a suppository composition comprising cannabinoids.
This Notice of Allowance is a continuation of AXIM’s patent (US 10,092,538 B2) granted to the Company in October 2018. Cannabinoids covered under the patent include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabinol (THC), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV), other cannabinoids, or a combination of all or some of these.
“AXIM has been recognized as an industry leader for its exceptionally valuable cannabinoid-based intellectual property portfolio and we are excited to add this patent to our robust pipeline of 8 patents and 13 pending patent applications,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “With this patent, we look forward to continuing our presence in the $77.13 billion global pain market while bringing much-needed options to millions of people across the world.”
[huge_it_slider id=”15″]The Company’s suppository composition is formulated for easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with nausea, vomiting, other conditions related to swallowing or conditions wherein suppository administration is required. Suppositories made under the patent will aim to reduce symptoms related to pain, nausea, postoperative ileus and/or inflammatory bowel disease (IBD).
Source: Company Press Release
